The week in health tech, explained in plain English.Get the free newsletter →
September 26, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

Crystalys Raises $130M for Gout Drug Dotinurad

By Healthcare Technology News ·

Crystalys Therapeutics has added $130 million in new financing to push its gout drug dotinurad through pivotal testing, MedCity News reports. Dotinurad is a URAT1 inhibitor, a class designed to help the body clear uric acid, the buildup of which drives the painful inflammation of gout.

Gout is one of the most common inflammatory conditions, yet treatment options remain limited and many patients fail to reach target uric acid levels on existing therapies. That gap is drawing fresh capital and dealmaking. Dotinurad works through the same mechanism as a molecule Sobi brought into its pipeline via a roughly $950 million acquisition, according to MedCity News, underscoring how large pharma is betting on the same target.

For Crystalys, the raise funds the expensive, late-stage trials needed to prove efficacy and safety before any regulatory filing. For the broader field, the money signals that investors see commercial upside in a prevalent, undertreated disease that has long lacked innovation.

Sources

More in Finance

Finance

UChicago Medicine Shifts Staff to Harder Revenue Cycle Work

UChicago Medicine is automating routine revenue cycle tasks and shifting staff to complex cases requiring human judgment.

Why it matters: It shows how hospitals can use automation to redeploy scarce revenue cycle talent rather than just cut jobs, easing margin and staffing pressure.

Finance

Oklahoma Health Campus Renamed After $150M Hamm Gift

Energy executive Harold Hamm's $150 million gift, the largest in University of Oklahoma history, will rename its Oklahoma City health campus home to OU Health.

Why it matters: Large philanthropic gifts are becoming essential capital for academic health systems operating on thin margins.

Finance

Chris Allen Named CFO of $6B UChicago Medicine

Chris Allen has been named executive vice president and CFO of the roughly $6 billion UChicago Medicine, returning to the system where he started as a budget analyst in the 1990s.

Why it matters: CFO leadership at large academic health systems is pivotal as hospitals fight to protect margins amid rising costs and heavy capital needs.